AirSense™
Expert care for asthma real-time monitoring.
What is AirSense?
Airsense™ is a wearable Class II medical device in development by DIA Labs Canada, designed for continuous asthma monitoring for up to 14 days. It uses advanced sensors, AI-driven analytics, and microneedle technology to collect respiratory data more comfortably and accurately than traditional methods.
Is Airsense™ FDA approved?
No, Airsense™ is currently under development and has not yet been cleared or approved by the FDA or any other regulatory authority. Regulatory submissions are part of our ongoing development process.
Who is Airsense™ intended for?
Airsense™ is being developed for individuals participating in asthma clinical trials, where continuous respiratory monitoring can offer more consistent and reliable data compared to conventional tools like spirometers or peak flow meters.
How is Airsense™ different from traditional asthma monitoring devices?
Unlike spirometers and peak flow meters, which require active user participation and are limited to point-in-time data, Airsense™ is passive, continuous, and designed to reduce user burden. Its combination of wearable tech, AI analysis, and minimally invasive microneedle sampling aims to deliver a more accurate and complete picture of respiratory health.
How long can Airsense™ be worn?
Airsense™ is designed to be worn continuously for up to 14 days, depending on clinical protocols and patient needs. Comfort, skin compatibility, and usability are key design priorities.
Is the microneedle technology painful?
No. Microneedle technology is minimally invasive and is engineered to be virtually painless, targeting the skin’s surface layer for non-disruptive sampling and monitoring.
Will Airsense™ be available for consumer or home use?
Currently, Airsense™ is being developed for clinical research and professional use only, with a focus on improving data quality in asthma clinical trials. Future consumer applications may be explored following regulatory approval.
Is the device reusable?
Airsense™ is being developed as a single-patient use device, with safety, hygiene, and data accuracy in mind. More information on use cycles will be provided as we advance toward regulatory submissions.
How is patient data managed and protected?
Data security and patient privacy are top priorities at DIA Labs Canada. Airsense™ is being developed with compliance to HIPAA, PIPEDA, and other applicable data protection regulations.
What is AirSense?
Airsense™ is a wearable Class II medical device in development by DIA Labs Canada, designed for continuous asthma monitoring for up to 14 days. It uses advanced sensors, AI-driven analytics, and microneedle technology to collect respiratory data more comfortably and accurately than traditional methods.
Is Airsense™ FDA approved?
No, Airsense™ is currently under development and has not yet been cleared or approved by the FDA or any other regulatory authority. Regulatory submissions are part of our ongoing development process.
Who is Airsense™ intended for?
Airsense™ is being developed for individuals participating in asthma clinical trials, where continuous respiratory monitoring can offer more consistent and reliable data compared to conventional tools like spirometers or peak flow meters.
How is Airsense™ different from traditional asthma monitoring devices?
Unlike spirometers and peak flow meters, which require active user participation and are limited to point-in-time data, Airsense™ is passive, continuous, and designed to reduce user burden. Its combination of wearable tech, AI analysis, and minimally invasive microneedle sampling aims to deliver a more accurate and complete picture of respiratory health.
How long can Airsense™ be worn?
Airsense™ is designed to be worn continuously for up to 14 days, depending on clinical protocols and patient needs. Comfort, skin compatibility, and usability are key design priorities.
Is the microneedle technology painful?
No. Microneedle technology is minimally invasive and is engineered to be virtually painless, targeting the skin’s surface layer for non-disruptive sampling and monitoring.
Will Airsense™ be available for consumer or home use?
Currently, Airsense™ is being developed for clinical research and professional use only, with a focus on improving data quality in asthma clinical trials. Future consumer applications may be explored following regulatory approval.
Is the device reusable?
Airsense™ is being developed as a single-patient use device, with safety, hygiene, and data accuracy in mind. More information on use cycles will be provided as we advance toward regulatory submissions.
How is patient data managed and protected?
Data security and patient privacy are top priorities at DIA Labs Canada. Airsense™ is being developed with compliance to HIPAA, PIPEDA, and other applicable data protection regulations.
What is AirSense?
Airsense™ is a wearable Class II medical device in development by DIA Labs Canada, designed for continuous asthma monitoring for up to 14 days. It uses advanced sensors, AI-driven analytics, and microneedle technology to collect respiratory data more comfortably and accurately than traditional methods.
Is Airsense™ FDA approved?
No, Airsense™ is currently under development and has not yet been cleared or approved by the FDA or any other regulatory authority. Regulatory submissions are part of our ongoing development process.
Who is Airsense™ intended for?
Airsense™ is being developed for individuals participating in asthma clinical trials, where continuous respiratory monitoring can offer more consistent and reliable data compared to conventional tools like spirometers or peak flow meters.
How is Airsense™ different from traditional asthma monitoring devices?
Unlike spirometers and peak flow meters, which require active user participation and are limited to point-in-time data, Airsense™ is passive, continuous, and designed to reduce user burden. Its combination of wearable tech, AI analysis, and minimally invasive microneedle sampling aims to deliver a more accurate and complete picture of respiratory health.
How long can Airsense™ be worn?
Airsense™ is designed to be worn continuously for up to 14 days, depending on clinical protocols and patient needs. Comfort, skin compatibility, and usability are key design priorities.
Is the microneedle technology painful?
No. Microneedle technology is minimally invasive and is engineered to be virtually painless, targeting the skin’s surface layer for non-disruptive sampling and monitoring.
Will Airsense™ be available for consumer or home use?
Currently, Airsense™ is being developed for clinical research and professional use only, with a focus on improving data quality in asthma clinical trials. Future consumer applications may be explored following regulatory approval.
Is the device reusable?
Airsense™ is being developed as a single-patient use device, with safety, hygiene, and data accuracy in mind. More information on use cycles will be provided as we advance toward regulatory submissions.
How is patient data managed and protected?
Data security and patient privacy are top priorities at DIA Labs Canada. Airsense™ is being developed with compliance to HIPAA, PIPEDA, and other applicable data protection regulations.
FAQ's
FAQ's
FAQ's